Introduction
Zebrafish represents an excellent in vivo model for drug discovery, enabling rapid screening of compound libraries for potential anti-cancer properties and in large parts, this is attributed to the rapid growth, high fecundity and transparent embryos, that allows real time in vivo imaging [1, 2] . Furthermore, the zebrafish genome share~70% homology to human genes, with significant overlap between signaling pathways that play key roles in zebrafish embryogenesis and human pathological conditions [3] [4] [5] .
Pertinently, Notch signaling is known to be highly active during trunk/tail development in the zebrafish [6] . This has been elegantly demonstrated using zebrafish mutants for example, after eight (aei)/deltaD, deadly seven (des)/notch1a, beamter (bea), and white tail (wit), whereby anterior somites formed normally but the posterior somites were profoundly disorganized with weak and irregularly spaced boundaries [7, 8] . Similarly, interfering with Notch activity with N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT) in developing zebrafish embryos, resulted in curvature of trunk and tail with boundary defects in somites, suggesting that this defective phenotype could be a useful readout to screen for molecules with the capability to interfere with the Notch pathway [9] [10] [11] .
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Besides its importance in embryogenesis, aberrant Notch activity is associated with several human pathological conditions including Alagille syndrome, CADASIL syndrome and Hadju-Cheney syndrome [12] . Furthermore, dysregulation of Notch signaling is frequently implicated in human cancers [13] [14] [15] [16] . For example, a sentinel study by Purow et al. [14] reported that NOTCH 1 and its ligands (DLL1, Jagged1) are overexpressed in glioma cells as well as primary lesions and down-regulation of these molecules by RNA interference resulted in inhibition of cell proliferation. More recently, Notch signaling has also been shown to play a role in tumor angiogenesis, maintenance of cancer stem cells and with data suggesting that high levels of Notch ligand DLL4, in both ovarian cancer and breast cancer may be viable as a predictive marker for resistance to anti-VEGF-A therapies [17, 18] . These observations broadly provide a rationale that the Notch pathway affords an attractive target for developing efficacious antagonists as therapies for treating pathological diseases with aberrant Notch activity.
Notch signaling essentially occurs when ligands from signal sending adjacent cells bind to the extracellular ligand-binding domain of the heterodimeric receptor complex that subsequently leads to its dissociation and proteolytic cleavage by ɣ-secretase, resulting in the release of the Notch intracellular domain (NICD) which then translocate to the nucleus to initiate transcriptional activity [19] . In this context, there has been a concerted effort to identify effective inhibitors of this pathway and several of these targeting the γ-secretase complex are currently under clinical evaluation [20] . Noteworthy examples include MK-0752 [21] , RO4909297 [22] and PF03084014 [23] . While these have shown promise against several advanced and metastatic solid tumors, they are associated with serious side effects that include gastrointestinal toxicity, hypertension and nausea [21, 24] . Therefore, an unmet need still remains to identify novel Notch antagonists that have minimal side effects but with increased specificity.
Natural products represent an important repository for discovering novel anti-cancer agents and to this end,~50% of the current anti-cancer therapies in clinical use are derived from natural products, for example, mitomycin-c, paclitaxel and irinotecan [25] . Thus, with the availability of a 234 compounds derived from the Malaysian biodiversity, we sought to identify if any of these have anti-Notch activity, using the zebrafish phenotypic assay as our primary screening platform followed by a secondary screen using human cell lines. From this approach, we have identified two compounds (EDD3, 3H4MB) that were consistently exhibiting defective trunk/ tail phenotype in developing embryos. Further screening using human cell lines suggested that these two compounds were likely interfering with Notch activity by preventing the accumulation of NICD and show promise for further development as bona fide Notch pathway antagonists.
Material and methods

Chemicals and drugs
Clinically relevant ɣ-secretase inhibitors targeting Notch signaling, N-[N-(3,5-difluorophenacetyl)-L-alanyl]-Sphenylglycine t-butyl ester (DAPT) and RO4939097, were purchased from SellekChem (TX, USA). The drugs were resuspended in dimethyl sulfoxide (DMSO; Sigma Aldrich, MO, USA) at 10 mM stock and stored at −20°C. The final concentration of DMSO was~1% in all experiments. Other chemicals used in this study included chloroform (Fisher chemicals, PA, USA), isopropanol (Merck, MA, USA) and ethanol (Fisher chemicals). All other chemicals used were from Sigma Aldrich.
Natural products
EDD3, a dammarane triterpenoids was purchased from ChemFaces (Hubei, China). Compounds 3H4MB and 3H4PP are curcumin derived diarylpentanoid analogues. 3H4MB was synthesized as previously reported [26] , and details for 3H4PP can be found in the Supplementary Material.
Zebrafish husbandry and zebrafish phenotypic assay
The Riken wild type (WT) zebrafish strain (Riken, Japan) was used in this study and maintained at 28°C on a 14 h-light/ 10 h-dark cycle. After spawning the fish, the embryos were placed in embryo media (E3) (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl 2 , and 0.33 mM MgSO 4 , pH 6.8-6.9) [27] prior to viewing under microscope (4× magnification) and only those observed to be uniformly dividing at~16-cell stage at 1.5 h post fertilization (hpf), were chosen for treatment at 3 hpf (1000 cells) [28] . A 10 embryo/well format (24-well plate) was employed for all screens. Unless indicated, for all experiments embryos were treated with a starting concentration of 40 μM of compounds and DAPT (50 μM) and RO4939097 (1 μM) were used as positive controls, while DMSO was used as a negative control was kept constant at 0.5%. Developmental phenotypic defects were observed at 3 days post fertilization (dpf) under microscope and results recorded as either normal, curved trunk/tail or death. All zebrafish experiments were carried out in compliance with UKMAEC ethical procedures (CARIF/2015/KAZUHIDE/25-MAR./ 673-JUNE-2015-DEC-2017).
Cell culture and transfection
HEK293T (Clontech Laboratories, CA, USA) cells were maintained in high glucose DMEM (Gibco, MA, USA) supplemented with 10% heat inactivated fetal bovine serum (FBS; Gibco) and 1% antibiotics (Gibco). The human oral cancer lines (ORL-48, ORL-150) were grown and maintained as previously described [29] . Transient transfection of HEK293T cells with pCS2 Notch ΔEMV-6MT construct (a kind gift from Dr Deming Chao, UPM, Malaysia) which essentially is the murine Notch1 gene that lacks the extracellular domain in the pCS2 vector was carried out following the protocol provided with the turbofect transfection reagent (Invitrogen, CA, USA). Unless indicated, for all experiments using human cell lines, the final concentration of DMSO (0.5%), DAPT (20 μM) and RO4939097 (20 μM), were kept constant.
Western blot analysis
After the indicated treatment, media was removed from the c e l l s f o l l o w e d b y w a s h ( P B S ) , l y s i s w i t h radioimmunoprecipitation buffer assay (RIPA) buffer (0.15 M NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris-HCl pH 8.0) containing protease and phosphatase inhibitor cocktail (Thermo scientific, MA, USA) and incubation on ice for 10 min. After, lysed cells were scraped and collected into microcentrifuge tubes followed by sonication for 10 s on ice (×3). Cell lysates were centrifuged at 4°C at maximum speed of 14,000 rpm for 15 min and the supernatant collected into fresh tubes. The protein concentration was next determined using the bicinchoninic acid assay (BCA) method following the manufacturer's protocol (Thermo Scientific). Next, 20 μg of total cellular lysates were resolved in 8-12% polyacrylamide gels followed by transfer onto immobilon-P polyvinylidene difluoride membrane (PVDF; Merck Millipore). Membranes were then probed for the indicated proteins following standard protocol as previously described [30] . All primary and secondary antibodies were used at 1:1000 and 1:10,000 dilution, respectively. Primary antibodies used included: Notch1 (#3608), Cleaved Notch 1 (NICD; #4147), Hes1 (#11988), and cleaved caspase-3 (Asp175) (all from Cell signaling technology; MA, USA). Cyclin D1 was purchased from Abcam (MA, USA) and purified mouse anti-human PARP antibody was purchased from BD Pharmingen (NJ, USA). Primary antibodies anti-actin (MAB1501) and anti-α-tubulin (T5168) (Sigma Aldrich) were used to detect housekeeping proteins.
Cell viability assay
ORL-48 and ORL-150 cells were plated in 96-well plates at 4000 cells/well and after overnight incubation cells were treated with DMSO, DAPT and test compounds serially diluted in media (100-0.4 μM) for 72 h. Primary human fibroblasts were seeded at 6000 cells/well and treated as indicated above. Viability of the cells was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (MTT). Each experiment was repeated three times.
Quantitative real-time PCR (qRT-PCR)
Total RNA from 40 embryos (~3 dpf) treated as indicated was extracted by homogenizing with 0.5 mL of Trizol (Invitrogen) in 1.5 mL tubes using syringe with a 22-gauge needle, while for adherent cells this done with mL of Trizol per well (6-well plate) and resulting lysates transferred to clean 1.5 mL microcentrifuge tubes. After incubation for 5 min at room temperature 250 μL of chloroform was added and tubes shaken vigorously for~15 s and allowed to further stand for 5 min at room temperature. Tubes were next centrifuged at 10,000 rpm for 5 min at room temperature and the aqueous phase, carefully collected into new tubes. Isopropanol (550 μL) was added to the aqueous phase and mixed gently at room temperature prior to centrifugation at maximum speed for 20 min at room temperature resulting in a translucent pellet at the bottom of each tube. After removing the liquid fraction in each tube, pellets were washed with 70% ethanol (×3). After washes, tubes were re-centrifuged to remove residual wash solution and briefly air-dried prior to re-suspending in ultrapure water (Invitrogen). After quantification by Nanodrop, 2 μg of total RNA was used as input to make template using the high capacity cDNA reverse transcription kit (Applied Biosystems, CA, USA) and the recommendations provided by the manufactures. The quality of cDNA was checked using gel electrophoresis using GAPDH primers and 1.5% agarose gel. qRT-PCR for the indicated genes was done with the SYBR green PCR master mix using 0.1 μg of cDNA template and the Applied Biosystem 7500 qPCR machine. Primer sequences for the genes analyzed for expression levels are listed in the Supplementary Table 1. All primers were designed to span the exon-intron boundary to minimize genomic DNA contamination. Primers were purchased from Integrated DNA Technologies (IDT, IA, USA). Crossing threshold values for individual genes were normalized to GAPDH. Relative expression of mRNA was determine using the formula: 2 -ΔΔCt , where ΔΔCt = −(ΔCt -ΔCt (control) and ΔCt = (target Ct -housekeeper Ct). Changes in mRNA expression were expressed as fold change relative to control.
Luciferase reporter assay
The assay was performed essentially as described by Sail, Hadden [31] . Briefly, HEK293T cells with a seeding density of 2 × 10 4 cells/well were grown in 96 well plates coated with poly-L-lysine. Cells were transfected with 0.3 μg pHes1(467)-luc responsive firefly luciferase reporter construct (a kind gift from Dr Deming Chao, UPM, Malaysia) containing the murine Hes1 promoter (−467 to +46), using 0.4 μL of turbofect reagent for each transfection reaction. Following 24 h post transfection, culture media was changed and cells were then treated with DAPT (20 μM) and the test compounds (10-40 μM) and incubated for an additional 48 h. After, cells were lysed with One-Glo Luciferase Reporter Assay System (Promega, WI, USA) and luminescence was measured using the Synergy H1 microplate reader (BioTek, state, VT, USA). Each experiment was done in triplicates.
Click-iT cell proliferation assay
Cell proliferation was evaluated using a modified EdU assay (Click-iT; Invitrogen). ORL-48 and ORL-150 cells were plated onto coverslips at 8 × 10 4 cells, in 12-well plates. After overnight incubation, cells were treated with DMSO or EDD3 (10, 20, 40 μM) and incubated for 24 h followed by an additional 2-6 h in the presence of 10 μM EdU. Cells were then fixed in 3.7% formaldehyde and permeabilized using 0.5% Triton X-100 in PBS. EdU was conjugated to Alexa Fluor 647 azide using the Click-iT reaction protocol and after the cell nuclei were counterstained with Hoechst 33,342 supplied with the kit. Stained cells were washed before being mounted on glass microscope slides using Vectashield Mounting Medium (Vector Laboratories, CA, USA) and examined with an upright Olympus IX71 microscope (Olympus, Japan) with the capability to detect fluorescent-stained cells (Hoechst 33342: excitation 360-370 nm and emission 420 nm; Alexa 647: excitation 650 nm and emission 667 nm). Images of stained cells were captured from 10 different fields in each treatment condition and analyzed as previously described [29] . Briefly, the captured images were analyzed with EBImage and proliferating cells were expressed as the percentage of EdU positive nuclei over the total number cells reflected by DAPI-stained nuclei. All experiments were repeated three times.
Cell cycle analysis
Cell cycle distribution was analyzed by flow cytometry. ORL-150 cells were collected after 24 h of treatment with 0.5% DMSO and test compounds at the indicated concentrations. After washing with PBS cells were fixed with 70% ethanol on ice and stored at −20°C until analysis. Fixed cells were washed with cold PBS and stained by incubating with propidium iodide (PI; Sigma-Aldrich) working solutions (10 μg/mL) containing RNase (Sigma-Aldrich) at 20 μg/mL for 30 min on ice under dark. The stained cells were next subjected to cell cycle analysis using FACSCanto II operated by BD FACS Diva software (BD Biosciences, NJ, USA). Results were further analyzed by using ModFit version 4 (Verity Software House, ME, USA). Experiments were repeated three times.
Statistical analysis
All statistical analysis was done using Graphpad prism 5.0 (GraphPad Software Inc, CA, USA). Results are given as mean ± SEM. Analysis was performed using a two-tailed unpaired, Student's t-test. Differences were considered significant with P ≤ 0.05.
Results
Identification of 3 novel compounds with potential anti-Notch activity in zebrafish embryos
To optimize a zebrafish phenotypic assay to identify potential antagonists of Notch signaling, we first treated whole embryos (3 hpf; 1000 cell stage) with DAPT and RO4929097 and monitored the resulting developing embryonic defects (3 dpf). As mentioned earlier, defects indicative of disruption of somitogenesis were observed in embryos treated with DAPT and RO4929097 in the form of disrupted somite boundaries (indicated by arrows) as early as 1 dpf ( Figure S1a ), which subsequently impacted normal trunk development (trunk curvature) as early as 2 dpf, becoming more pronounced by 3 dpf when compared to control ( Figure S2a-c) . Although somitogenesis defects were observed earlier, trunk formation defect was easier to score and thus the curved trunk/tail phenotype was chosen for subsequent screening purpose and a window of 3 dpf was chosen for all primary screens of our compounds. As indicated in Fig. 1 , a total of 234 compounds from our library collection of plant and microbial origin (terpenes and flavonoids) and synthetic diarylpentanoids and indole origin, were subjected to zebrafish phenotypic assays using an initial concentration of 40 μM and embryos at 3 hpf. This initial concentration was chosen as this was lower than that used for DAPT in developing embryos and with the premise that this may minimize false positives. From this initial screen, 3 compounds (EDD3, 3H4MB, 3H4PP) exhibited a characteristic trunk curvature similar to those observed for embryos treated with DAPT and RO4929097 ( Figure S2d) . Nonetheless, this concentration gave our screen a hit rate of 1.3%, and as mentioned by Brady et al. [32] , a desired hit rate should be between 0.5 and 1%.
EDD3 and 3H4MB identified as potential Notch antagonists in vitro in HEK293T overexpressing Notch1
Prior to subjecting the 3 compounds to secondary screens, we aimed to optimize our experimental conditions that included optimal concentrations of the compounds to use in our subsequent analysis. Firstly, we opted to overexpress the truncated Notch1 (ΔE) in HEK293T cells (subsequently referred as HEK293TΔE) and as seen in Figure S3a -b, this resulted in the accumulation of NICD (Notch intracellular domain), an indication of pathway activation when compared to control. Notably, DAPT and RO4929097 at 20 μM were both able to reduce the accumulation of NICD over 24 and 48 h of treatment. Lower concentrations of both inhibitors were not optimal to reduce NICD accumulation (data not shown). Also noted, endogenous NOTCH1 levels were readily detected and with marginal differences between control and treated cells. We also observed that 48 h treatment with DAPT and to a lesser extent RO4929097, resulted in lower protein levels of HES1, a downstream target of the Notch signaling, while this reduction was not observed with 24 h treatment. Based on these results, we concluded that HEK293TΔE could be utilized for evaluating compounds targeting Notch signaling including ɣ-secretase and that a treatment time of 48 h was optimal for achieving an efficient reduction in NICD compared to 24 h of treatment. Subsequently, we evaluated EDD3, 3H4MB and 3H4PP using this secondary screening platform.
From our analysis of the chemical structures, we noted that EDD3 and 3H4MB consisted of dammarane triterpenoids (20S,24R-epoxydammar-12β,25-diol-3-one and a curcumin-derived diarylpentanoid analogue (2-benzoyl-6-(3-hydroxy-4-methoxy) benzylidenecyclohe xanone, respectively (Fig. 2a-b) . For assessing an optimal concentration of these compounds in our secondary screens, we chose a range of 10-40 μM and noted that both compounds were observed to interfere with Notch activity where levels of NICD and HES1 were reduced with 20-40 μM (Fig. 2c-d) . Of note, both compounds at 40 μM reduced NOTCH1 levels. All experiments were compared with DMSO and DAPT. In contrast, compound 3H4PP (a pyrrole-containing chalcone; Figure S4a ) as shown by representative western blot showed minimal inhibitory effect on Notch signaling and as note, protein levels of NOTCH1 were not assessed ( Figure S4b) . Collectively, our in vivo and in vitro analysis identified EDD3 and 3H4MB when used at 20-40 μM as potential Notch signaling antagonists that warranted further validation.
EDD3 and 3HM4B had minimal effect on zebrafish somitogenesis
We next assessed the optimal concentration of the two compounds to use in our subsequent in vivo analysis and for this we treated embryos at 3 hpf in a dose dependent manner and as indicated, EDD3 exhibited normal phenotype with concentrations between 5 and 20 μM, while 40 μM resulted in a robust curvature of trunk/tail (30/30 embryos). On the other hand, 3H4MB demonstrated increased potency with curvature of trunk/tail being observed with 20 μM and 40 μM (30/30 embryos), while 5 and 10 μM giving a normal phenotype (Fig. 3a-b) . Consequently, 40 μM and 20 μM were chosen for EDD3 and 3H4MB, respectively, for subsequent in vivo experiments. As Notch signaling is essential for zebrafish somitogenesis, we evaluated the effect of the compounds on somitogenesis by characterizing somite boundary formation in treated embryos at 24 hpf. Embryos treated with EDD3 and 3H4MB showed some embryos with disruption to posterior somites whereby EDD3 treated embryos displayed a mixture of normal somites with slightly curved tail (n = 7/15) and embryos showing mild disruptions to somites (n = 8/15, 53% of embryos). 3H4MB treatment also resulted in a mixture of Fig. 1 Primary and secondary screens for identifying potential antiNotch molecules. Schematic shows the strategy used for screening natural products (plants, microbial, synthetic) using zebrafish. Embryos at 3 hours post fertilization (hpf) are exposed to stock compounds dissolved in embryo media (E3) media and changes to phenotype are observed at 3 day post fertilization (dpf). A straight trunk/tail phenotype is considered as normal development whereas curved trunk is associated with anti-Notch signaling. Positive hits are subsequently validated using HEK293T transfected with the pCS2 Notch ΔEMV-6MT (murine Notch1 gene lacking the extracellular domain (referred as HEK293TΔE) and interference of Notch signaling is assessed by western blot phenotypes, where some embryos showed normal somite formation (n = 3/15) while the majority showing disrupted posterior somites (n = 12/15, 82% of embryos) ( Figure S1b ). However unlike DAPT and RO4929097 treated embryos, and 3H4MB were observed at 3 dpf for development defects. Scale bar represents 500 μm. Numbers in bracket indicate number of embryos exhibiting the phenotype over total embryos tested (n = 30). Experiments were done in replicates. c-d Zebrafish embryos were treated with DMSO, DAPT (50 μM), EDD3 (40 μM) and 3H4MB (20 μM) and mRNA levels of hey1 and her6 were analyzed majority of somite boundaries particularly that of anterior somites formed normally in EDD3 and 3H 4MB treated embryos.
EDD3 and 3HM4B inhibits mRNA expression of Notch target genes in vivo and in vitro
We next evaluated mRNA levels of Notch target genes in zebrafish treated with EDD3 and 3H4MB and our qRT-PCR results indicated that mRNA levels of hey1 were reduced by 3.5 and 1.7 fold, respectively while giving a modest reduction for her6 (1.4 and 1.3 fold, respectively) ( Fig. 3c-d) . These results are also consistent with those of DAPT, which showed reduction in hey1 and her6 levels by 3.3 and 1.8 fold, respectively. As both compounds gave in vivo evidence of targeting mRNA levels of key Notch target genes, we next determined mRNA levels of human equivalent genes in treated HEK293T cells using 40 μM of EDD3 and 20 μM of 3H4MB. Genes including HEY1, HES5 and CYCLIN D1, which have been reported to be reliable indicators of Notch activity were evaluated in this study [33] . Our data indicated a significant reduction in HEY1 levels for EDD3 (4.2 fold) and 3H4MB (5 fold), comparable to treatment with DAPT (Fig. 4a) . HES5 mRNA levels were also reduced by treatment with both compounds (3.8 and 3 fold, respectively), however those for 3H4MB were assessed to be statistically not significant (Fig. 4b) . Also, as shown in Fig. 4c , both compounds reduced CYCLIN D1 mRNA levels but these were statistically insignificant when compared with control. We also verified our results using a HES1-responsive luciferase reporter system, specifically to determine if these compounds may be interfering with HES1 response genes. Using HEK293T cells overexpressing the reporter we observed that treatment with both EDD3 and 3H4MB (10-40 μM) for 48 h resulted in reduced HES1 luciferase activity in a dose dependent manner (Fig. 4d-e) . Notably, EDD3 was evoking a response at the lowest concentrations (10 μM) used compared to 3H4MB, where only the highest concentration (40 μM) gave a significant effect. Nevertheless, our data provide further in vitro and in vivo evidence that EDD3 and 3H4MB are likely Notch antagonists that also inhibit transcription levels of Notch signaling genes. However, HEK293TΔE represents an artificial system and a more physio-pathological relevant system, which endogenously expresses Notch pathway proteins, would be more optimal for testing these compounds.
EDD3 and 3H4MB interferes with Notch signaling in human oral squamous cancer cells
As recent data suggests that Notch signaling may be dysregulated in a sub-set of oral squamous cancers due to the presence of mutations in the NOTCH1 gene, we sought to assess if our compounds may have the capacity to interfere with this [29, [34] [35] [36] . From our preliminary data assessing endogenous levels of Notch related proteins, we noted that four lines (ORL-48, ORL-150, ORL-153, ORL-215) were demonstrating high NICD levels (data not shown) and based on these observations, we chose to focus on ORL-48 and ORL-150 for our subsequent studies for evaluating EDD3 and 3H4MB. As shown in Fig. 5a , NOTCH1, NICD and HES1 proteins were readily detected in these cell lines while HEK293TΔE used as a positive control, where the truncated form of Notch1 protein was detected at~80 kDa. Next, we sought to experimentally verify whether the Notch pathway is active in these lines by determining if DAPT and RO4929097 could interfere with the observed NICD accumulation. Thus, treatment of cells with both inhibitors showed that NOTCH1 levels were largely unaffected while those of NICD and HES1 were markedly reduced when compared to control (Fig. 5b) . As the Notch pathway was found to be detectable and functional in these lines, we next investigated if the two compounds would have a similar effect but before testing we assessed their IC 50 values and found that both lines were sensitive to EDD3 treatment at 27-29 μM. By contrast, 3H4MB conferred less sensitivity to (Figure S5a-b) .
Moreover, both the compounds tested had a minimal impact on the viability of primary human fibroblast cells (IC 501 00 μM) ( Figure S5c ). As EDD3 was demonstrating better sensitivity in these cells, we opted to work with this compound for further determining interference of Notch activity. As shown in Fig. 5c , EDD3 treatment of ORL-48 reduced NICD levels at the highest concentration (40 μM) while those of HES1 remained unaffected as shown by densitometry (Figure S6a-b) . Protein levels of CYCLIN D1 also demonstrated a similar profile as those observed for NICD. By contrast, ORL-150 cells treated with EDD3 resulted in a dose dependent reduction of NICD and with complete loss of protein expression observed with 40 μM of treatment (Fig. 5d) . CYCLIN D1 levels were also reduced in a similar dose dependent manner while those of HES1 and NOTCH1 (shown by densitometry in Figure S6c) were marginally reduced and remained unaffected, respectively (Fig. 5d) . As ORL-150 cells were demonstrating increased sensitivity to EDD3 when compared to ORL-48, we used these cells treated with the EDD3 (40 μM) to evaluate mRNA levels of Notch target genes and noted that expression of HEY1, HES5 and CYCLIN D1 were significantly reduced (~2.4, 4.7 and 3.5 fold, respectively), suggesting that the compound is likely interfering with Notch activity in ORL-150 cells (Fig. 5e-g ).
EDD3 inhibits proliferation and cell cycle progression of ORL-150 cells
As Notch signaling is known to play a role in cell proliferation, differentiation and apoptosis [37, 38] , we investigated the impact of EDD3 on these cancer hallmarks in ORL-150. As shown in Fig. 6a-b, EDD3 was observed to exert a significant anti-proliferative effect using the optimal conditions assessed (40 μM for 24 h). Consistent with these observations and using the same conditions, our cell cycle analysis also indicated an increase in a cell population at G 0 /G 1 , however this effect was not as robust as expected likely reflecting a shorter treatment period. Thus, we tested with a higher amount of the compound (80 μM) and noted that the effect was more (Fig. 7a-b) . We next focused on analyzing the effect of EDD3 on G 0 /G 1 cell cycle proteins. Treatment with EDD3 (80 μM) marginally reduced the amounts of CYCLIN D1 and CYCLIN E1 while those of p27 KIP1 were induced. No changes in p21 WAF1 were noted and TUBULIN was used as loading control (Fig. 7c) . Interestingly, similar analysis using ORL-150 cells treated with DAPT and RO4929097 did not elicit any cell cycle arrest or changes in related proteins ( Figure S7a-d) . We also noted that the high concentration used (80 μM) in our cell cycle analysis did not elicit a profound apoptotic process. As shown in Figure S8a , treatment of cells with EDD3 with the indicated concentrations did not result in extensive cell death with regards to morphological changes when compared with control treatment. Furthermore, cell cycle analysis with the same set of cells, did not result in a notable accumulation in sub-G 1 (Figure S8b-f) . Assessment of apoptosis markers showed that increasing treatment dosage of EDD3 did not cause PARP cleavage, but did result in a minimal increase in cleaved caspase 3 when compared to control. Also, we were able to show as mentioned earlier, that EDD3 treatment resulted in decreased cyclin D1 levels and induction of p27 KIP1 ( Figure S8g ). Our data suggests that EDD3 is likely interfering with Notch activity which impacts cell proliferation through the induction of p27 KIP1 .
Discussion
Zebrafish has been widely utilized as a robust drug-discovery screening model to identify potential novel small molecule therapeutics [1, 39, 40] . Using a similar approach, we provide evidence that two natural product derived compounds, EDD3 and 3H4MB demonstrated promising anti-Notch activity using an optimized zebrafish phenotypic assay, giving a consistent curved trunk/tail phenotype.
EDD3, a dammarane triterpenoid, has been previously identified from the root of Salvia bicolor and as there is limited information on the bioactivity of the compound, affords value for further in depth evaluation. 3H4MB on the other hand, represents a novel diarylpentanoids curcumin analog from a series of 29 that were synthesized with the rationale to improve bioavailability [26] and currently remains unexplored. The identification of these two novel compounds targeting Notch signaling in our system, highlights the fact that developing zebrafish embryos are amenable for rapid identification of natural product derived compounds with potential to interfere with key signaling pathways that are important and pathological in embryogenesis and human cancers, respectively [41] [42] [43] .
While there are several cell-free and cell-based assays for identifying Notch pathway antagonists, this study offers additional benefit as it involves whole organism based screening [44, 45] , which enables identification of promising compounds with in vivo efficacy and minimal teratogenicity. In this regard,~65 small-molecule screens conducted by several groups have utilized phenotypic readouts for example, haematopoietic stem cell and hair cell development, trunk formation, heart rate, pigmentation, motor activity and craniofacial morphology among many, and have successfully identified Prohema [46] , dorsomorphine [47] and proto-1 [48] as promising hits to follow. Phenotype based screens offers many advantages but it is limited with high occurrence of false positive as multiple pathways can result in similar phenotypes. For example, apart from Notch signaling, inhibition of Shh and MAPK can also result in a trunk/tail phenotype [6] . To overcome this, we combined our zebrafish phenotypic screen with a secondary screen using HEK293TΔE cells to exclude compounds such as 3H4PP that although showed a similar curved trunk/tail phenotype in the zebrafish phenotypic assay, did not inhibit Notch signaling in the mammalian system. It is worth mentioning however, that while our observations suggest that EDD3 and 3H4MB are likely targeting Notch activity, we cannot exclude the possibility that they could be functioning differently from known ɣ-secretase inhibitors leading to variations in trunk/tail curvature defects. In support, we demonstrated that EDD3 and 3H4MB cause only mild disruption to posterior somites unlike DAPT and RO4929097, which causes extensive defects to somites. Further, the direction of trunk curvature between ɣ-secretase inhibitors and the compounds treated embryos differed. DAPT and R04929097 treated embryos curved upwards (dorsal curve) whereas, compound treated embryos curved sideways (lateral curve) ( Figure S2b-d) . We speculate that unlike ɣ-secretase inhibitors, the compounds are likely not affecting key genes involved in somitogenesis such as her1 and her7 but targeting elsewhere in this pathway. Although the compounds show a reduction in hey1 and her6 mRNA levels in zebrafish, her6 has been shown previously to not to play a role in somitogenesis [49] and hey1 has not been associated with somitogenesis. Nonetheless, the consistent curved trunk/tail phenotype shown by EDD3 and 3H4MB combined with promising reduction in NICD in vitro, suggests that these compounds warrant further investigation.
As mentioned earlier, several studies have now implicated dysregulation of Notch signaling in a sub-set of human head and neck squamous cancers due to the high frequency of mutations detected in the NOTCH 1 gene [34, 35] and consequently, this prompted us to evaluate a well characterized panel of oral cancers cell lines for endogenous Notch activity for the possibility of validating these compounds [29] . From our observations we noted that two lines (ORL-48, ORL-150) demonstrated the presence of an active Notch signaling pathway as indicated by the presence of NICD and the attenuation observed with both DAPT and RO4929297 treatment. Of interest, EDD3 reduced levels of NICD and CYCLIN D1 in ORL48 and ORL150 cells, suggesting that these cancer lines may potentially be used as screening tools for novel inhibitors of the Notch pathway. While we observed marginal reduction in HES1 levels we postulated that this could be due to convergence of other oncogenic pathways for example, Wnt, hedgehog, RAS and JNK signaling [50, 51] . With regards to this, a recent study reported that attenuation of Notch signaling was found to impair breast cancer recurrences in vivo, but levels of HES1 remained unchanged likely due to signaling through FGFR and ErbB2 [52] . Pertinently, in the same study, the use of MRK-003 was able to reduce the tumor burden in a minimal residual disease mouse model of breast cancer, suggesting a benefit for breast cancer patients that have undergone therapy with inhibitors targeting Notch signaling either as adjuvant or in combination with HER2 targeted therapies. In the same context, a recent study demonstrated that contact between differentiated keratinocytes and melanocytes in the epidermal microenvironment resulted in Notch activation in metastatic melanoma which was independent of acquired driver mutations, suggesting that inhibitors targeting this pathway may have value as therapy for patients with this disease [53] .
From our investigation, we also observed a notable reduction in CYCLIN D1 levels with EDD3 in ORL-150 and questioned if cell cycle progression was compromised and noted that this compound was causing the cells to accumulate in G 1 , likely through the concurrent induction of p27 KIP1 . In support of these observations, Sjolund et al. [16] , reported that human clear cell renal cell carcinoma lines were essentially harboring constitutively active Notch signaling that was independent of the causal VHL/HIF pathway. Thus, by using siRNA targeting Notch1 in these cells, effectively lead to elevations in p21 WAF1 and p27 KIP1 levels indicative of G 1 arrest. Furthermore, interfering with the Notch pathway in T-ALL cells using MRK-003 also showed up-regulation of p27 KIP1 and p19
INK4D [54] . This indicates that induction of these cyclin dependent kinase inhibitors might represent potential mechanism by which interfering with the Notch pathway impacts cell proliferation and explain in part, our observations that EDD3 is likely inhibiting cell proliferation through increased levels of p27 KIP1 . Notwithstanding, several limitations need mentioning. Firstly, high concentrations of EDD3 and 3H4MB are required to confer inhibition of Notch activity when compared to known ɣ-secretase inhibitors. Nonetheless, our study has potentially contributed to identifying new antiNotch compounds with different chemical scaffolds, where the potency could be likely improved further by structure modification. This has been demonstrated by paclitaxel where synthetic modification has been conducted to yield docetaxel with better potency [55] . Secondly, the precise mechanism by which EDD3 exerts the observed anti-Notch activity needs further investigation, as there are differences in the mode of action between this compound and the ɣ-secretase inhibitors used (DAPT and RO4929097). This could be partly due to the absence of the synthetic cyclic structure and fluorine moiety on a diverse core skeleton commonly observed in ɣ-secretase inhibitors, in EDD3 [20] . This potentially highlights the fact that EDD3 could impact Notch signaling pathway not through the inhibition of ɣ-secretase but elsewhere in this pathway and this is yetto-be determined. Furthermore, a defective trunk/tail development in a phenotypic screen represents an efficient and fast method but not definitive for inhibition of Notch activity. In this context, Notch reporter zebrafish transgenic lines such as Tg(Tp1bglob:eGFP) um13 ;Tg(Tp1bglob:hmgb1-mCherry) jh11
and Tg(EPV.Tp1-Mmu.Hbb:nlsmCherry) 197 [56, 57] could complement the current screening platform with better specificity and sensitivity. These transgenics utilize the Notchresponsive box that contains copies of the Epstein Barr Virus terminal protein 1 (TP1) promoter elements containing multiple RBP-Jĸ binding sites and when NICD and its cofactor RBP-Jĸ bind at these sites, drive the expression of the fluorophores, enabling observation of temporal and spatial pattern of Notch signaling in vivo [58] .
In summary, our results provide evidence that EDD3 and 3H4MB have potential to modulate Notch signaling and EDD3 specifically hold promise as oral cancer cells tested demonstrated higher sensitivity to this compound.
